SCHEMBL4533134

SCHEMBL4533134

Cc1cc(Nc2nc(N3CC4(CCN(S(C)(=O)=O)CC4)C3)nc3ncccc23)[nH]n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 10/20 0.48
▸ ALDH1A1 P00352 10/20 0.48
▸ HPGD P15428 7/20 0.48
▸ CYP3A4 P08684 4/20 0.48
▸ USP2 O75604 3/20 0.48
▸ CYP2D6 P10635 7/20 0.42
▸ CYP1A2 P05177 7/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ CYP2C19 P33261 6/20 0.40
▸ CYP2C9 P11712 6/20 0.40
▸ TSHR P16473 4/20 0.40
▸ HIF1A Q16665 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SMO Q99835 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4526646 0.87 HSD17B10 (0.44) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL4511804 0.87 ALDH1A1 (0.44) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL4512984 0.84 HSD17B10 (0.49) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL4535745 0.83 ACACB (0.41) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL4529942 0.81 PAK4 (0.39) HSD17B10ALOX15TSHRSMN1; SMN2KMT2A
SCHEMBL5314611 0.79 PAK4 (0.34) —
SCHEMBL4521403 0.79 WHR1 (0.43) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL4519095 0.79 HSD17B10 (0.41) HSD17B10ALDH1A1HPGDCYP3A4USP2
SCHEMBL4524529 0.77 JAK3 (0.34) —
SCHEMBL4531067 0.75 PAK4 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831216-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2007-09-12 — — EP claimed
WO-2006067614-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2006-06-29 — — WO claimed
US-20090281073-A1 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS BHATTACHARYA SAMIT KUMAR 2009-11-12 — — US disclosed
EP-1831216-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2007-09-12 — — EP disclosed
WO-2006067614-A2 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2006-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281073-A1 HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS CCNY, TP53, CCNE1 HSD17B10 944/4885ALDH1A1 772/4885HPGD 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback